Market Place
Sourcing Support
Invitation to Sobi`s Q1 2026 Report
14 Apr 2026 //
PR NEWSWIRE
Sobi Releases 2025 Annual & Sustainability Report
31 Mar 2026 //
PHARMIWEB
Swedish Orphan Biovitrum AB Announces Annual General Meeting
27 Mar 2026 //
PR NEWSWIRE
Sobi Capitalizes On Ambition, Aiming For SEK 55Bn By 2030
18 Feb 2026 //
PR NEWSWIRE
Sobi To Host A Capital Markets Day On 18 February 2026
11 Feb 2026 //
PR NEWSWIRE
Sobi Reports Strong Growth And Progress In Q4 And FY 2025
05 Feb 2026 //
PR NEWSWIRE
Sobi Exceeds Previous Outlook With 2025 Revenue And EBITA Margin
15 Jan 2026 //
PR NEWSWIRE
Invitation to Sobi`s Q4 & FY 2025 Report
14 Jan 2026 //
PR NEWSWIRE
Sobi To Host Capital Markets Day On February 18, 2026
18 Dec 2025 //
PR NEWSWIRE
Olezarsen Pivotal Study Results In Severe Hypertriglyceridemia
08 Nov 2025 //
PR NEWSWIRE
Sobi Updates Full-Year Outlook & Accelerates Q3 Financial Report
20 Oct 2025 //
PR NEWSWIRE
Sobi Q3 2025 Report: Accelerated Growth And Portfolio Momentum
20 Oct 2025 //
PR NEWSWIRE
New Number Of Shares And Votes In Sobi
30 Sep 2025 //
PR NEWSWIRE
Invitation: Sobi`s NASP Webcast on Uncontrolled Gout
10 Sep 2025 //
PR NEWSWIRE
New number of Share and Votes in Sobi
30 Aug 2025 //
PR NEWSWIRE
Sobi Completes Class C Shares Issue
21 Aug 2025 //
PR NEWSWIRE
Sobi`s Q2 2025 Report Shows Strong Portfolio & Pipeline Momentum
16 Jul 2025 //
PR NEWSWIRE
Sobi Board Authorizes Share Repurchase for Incentive Programs
15 Jul 2025 //
PR NEWSWIRE
Invitation: Sobi`s Q2 report
02 Jul 2025 //
PR NEWSWIRE
Sobi`s Aspaveli® 52-week Phase 3 Valiant Data in Nephrology
03 Jun 2025 //
PR NEWSWIRE
Bulletin from Sobi`s Annual General Meeting (AGM)
08 May 2025 //
PR NEWSWIRE
Sobi publishes Q1 2025 report: Portfolio continues to deliver
29 Apr 2025 //
PR NEWSWIRE
Sobi, Sanofi`s Foundation extend partnership with WFH Humanitaria
25 Apr 2025 //
PRESS RELEASE
Sobi presents clinical data at WFH 2025 Comprehensive Care Summit
23 Apr 2025 //
PR NEWSWIRE
Invitation: Sobi`s Q1 report
15 Apr 2025 //
PR NEWSWIRE
EMA Validates Aspaveli Indication Extension For C3G & IC-MPGN
20 Feb 2025 //
PR NEWSWIRE
Sobi publishes Q4 2024 report: A solid ending to a strong year
05 Feb 2025 //
PR NEWSWIRE
Invitation: Sobi`s Q4 and FY 2024 report
21 Jan 2025 //
PR NEWSWIRE
Sobi`s full year 2024 revenue higher than previous estimate
10 Jan 2025 //
PR NEWSWIRE
Sobi`s FDA Acceptance of Avatrombopag NDA for Pediatric ITP
12 Dec 2024 //
GLOBENEWSWIRE
Bulletin from Sobi`s Extraordinary General Meeting (EGM)
11 Dec 2024 //
PR NEWSWIRE
Sobi`s strength in haematology to be showcased at ASH 2024
03 Dec 2024 //
PR NEWSWIRE
David Meek is proposed as new Chair of Board of Directors of Sobi
05 Nov 2024 //
PR NEWSWIRE
David Meek Proposed as New Chair of Sobi Board of Directors
04 Nov 2024 //
PR NEWSWIRE
Invitation: Sobi`s Aspaveli® Phase 3 VALIANT Data Call
25 Oct 2024 //
PR NEWSWIRE
Sobi Reports Strong Growth And Pipeline Momentum In Q3 2024
24 Oct 2024 //
PR NEWSWIRE
New number of shares and votes in Sobi
30 Sep 2024 //
PR NEWSWIRE
Sobi &Enable Injections Partner On Aspaveli With enFuse System
12 Sep 2024 //
GLOBENEWSWIRE
Sobi has completed issues of class C shares
29 Aug 2024 //
PR NEWSWIRE
Sobi And Apellis Report Positive Results From Pegcetacoplan Study
09 Aug 2024 //
PR NEWSWIRE
NEJM Publishes ALTUVOCT® Phase 3 Results For Pediatric Hemophilia A
17 Jul 2024 //
PRESS RELEASE
Sobi boosts hematology sales with growth across key brands
16 Jul 2024 //
FIERCE PHARMA
Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance
16 Jul 2024 //
PR NEWSWIRE
Sobi Board Exercises Share Repurchase Authorization For Incentive Programmes
15 Jul 2024 //
PR NEWSWIRE
Invitation: Sobi`s Q2 2024 report
03 Jul 2024 //
PR NEWSWIRE
Sobi gets EU okay for long-acting haemophilia A drug
20 Jun 2024 //
PHARMAPHORUM
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
24 May 2024 //
GLOBENEWSWIRE
Bulletin from Sobi`s Annual General Meeting (AGM)
14 May 2024 //
PR NEWSWIRE
Sobi’s Aspaveli obtains indication extension approval in Europe
09 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Aspaveli Approved In Europe For Treatment Naïve PNH Patients
08 May 2024 //
PR NEWSWIRE
Sobi Completes SEK 3 Billion Senior Bond Issue
08 May 2024 //
PR NEWSWIRE
Sobi Establishes SEK 10B MTN Programme, Base Prospectus
26 Apr 2024 //
PR NEWSWIRE
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
25 Apr 2024 //
PR NEWSWIRE
Sobi publishes Annual and sustainability report for 2023
02 Apr 2024 //
PR NEWSWIRE
Orexo and Sobi agree to advance feasibility study with AmorphOX
12 Feb 2024 //
PR NEWSWIRE
Invitation: Sobi`s Q4 and FY 2023 report
24 Jan 2024 //
PR NEWSWIRE
Sobi`s Chairman of the Board resigns due to health reasons
05 Jan 2024 //
PR NEWSWIRE
Sobi to present new data at ASH 2023 Annual Meeting
20 Nov 2023 //
PR NEWSWIRE
Health Canada Approves DOPTELET for Two Indications in Thrombocytopenia
06 Nov 2023 //
GLOBENEWSWIRE
Sobi issues series C shares to fulfil its obligations
31 Oct 2023 //
PR NEWSWIRE
